Got map? Shares of Celera <% if gsSubBrand = "aolsnapshot" then Response.Write("(NYSE: CRA)") else Response.Write("(NYSE: CRA)") end if %> moved higher earlier this week on speculation that the company had completed the worthy task of mapping the human genome. What did I just say? What does it mean? Let's have two Fools from opposite sides of the fence explain it all away.

Paul Larson (TMF Parlay) is bullish over the prospects of the most recent Rule Breaker addition. Bill Barker (TMF Max) thinks the shares themselves may be going in for a little splicing. Let's don our lab coats and put this one under the microscope.

Once you're done slicing and splicing the arguments, don't forget to vote for the side that moved you. Then, why not join us as we go back six months to revisit who won and who lost the Yahoo! <% if gsSubBrand = "aolsnapshot" then Response.Write("(Nasdaq: YHOO)") else Response.Write("(Nasdaq: YHOO)") end if %> bout in our Duel Flashback feature.

The Bull Argument... Today, Celera Genomics is in the process of fully decoding the human blueprint on the atomic level. This is the information age, and the information Celera is mining is among the most important chunks of knowledge to come our way in some time. Continue »

The Bear Argument... Even the staunchest, most informed, most enthusiastic Celera bull will have to admit that Celera is one of the more difficult companies to figure out. Where the profits will come from, when profits might arrive, what's the state of the competition -- all of these are open to a great deal of speculation. Continue »

The Bull Argument »

 This Week's Duel